How do stem cell donor coordinators explain G-CSF mobilization to Spanish-speaking donors?

G-CSF mobilization is one of the most alarming experiences a peripheral blood stem cell donor encounters, because the drug produces blood count changes that, in any other context, would indicate a medical emergency. A WBC of 60,000 to 80,000 with a left shift and a platelet count of 90,000 to 100,000 looks like leukemia or acute bone marrow failure to a lay person who has ever seen normal lab values. When the donor who receives these results is Spanish-speaking and has no prior framework for what G-CSF does, the likelihood of a panicked call — or a canceled donation — is very high. The explanation the donor coordinator must give in advance, before day four of the G-CSF course, requires three components. First, what G-CSF is doing to the bone marrow: hematopoietic stem cells normally live and divide inside the bone marrow in specific physical niches. They do not circulate in the bloodstream in significant numbers under normal conditions. G-CSF (filgrastim) is a synthetic version of a protein the body produces naturally when the marrow needs to produce more cells rapidly — after a severe infection, for example, or after chemotherapy damages the marrow. When given at the doses used for stem cell mobilization — subcutaneous injection for five consecutive days — it drives rapid expansion of the stem cell population in the marrow and simultaneously loosens the molecular anchors that hold stem cells in their marrow niches. The stem cells pour out of the marrow into the bloodstream. The WBC count rises dramatically — not because of leukemia, but because the marrow is doing exactly what the medication instructed it to do. Second, why bone pain occurs: the marrow cavities — inside the sternum, ribs, pelvis, long bones — are expanding their cell population so rapidly that they become engorged. The periosteum, which lines the outer surface of the bone, is pressure-sensitive. As the marrow fills, pressure rises against the periosteum, producing the characteristic aching, deep bone pain that affects most donors during G-CSF mobilization, worst at day four and five. Ibuprofen or acetaminophen blunts it; the pain is expected and resolves within 24 hours of the last G-CSF injection. Third, why platelets drop: as the stem cells flood out of the marrow into the bloodstream, the marrow's production of other cell lines — platelets, in particular — is temporarily diverted. Platelet counts of 80,000 to 110,000 are common on the morning of apheresis. This is the expected lab picture of successful mobilization, not a sign of platelet consumption or bleeding risk at the donation volumes collected. The coordinator explaining this in Spanish before day four of G-CSF: '“El G-CSF va a hacer que sus conteos de glóbulos blancos suban mucho — quizás a 60,000, quizás más. Y es posible que sus plaquetas bajen un poco al mismo tiempo. Eso parece muy alarmante si usted lo ve sin contexto. Pero eso es exactamente lo que necesitamos que pase. El medicamento está empujando las células madre fuera de la médula hacia la sangre, y la subida de glóbulos blancos es la prueba de que el medicamento está funcionando. La médula está haciendo lo que le pedimos que hiciera. Si llama a una sala de urgencias con esos conteos sin mencionar el G-CSF, le van a hacer muchas preguntas. Por eso necesito que tenga este número y me llame a mí primero si ve resultados que le preocupen.”' (The G-CSF is going to make your white blood cell counts rise a lot — maybe to 60,000, maybe more. And your platelets may fall a bit at the same time. That looks very alarming if you see it without context. But that is exactly what we need to happen. The medication is pushing stem cells out of the marrow into the blood, and the rise in white blood cells is the proof that the medication is working. The marrow is doing what we asked it to do. If you call an emergency room with those counts without mentioning the G-CSF, they are going to ask many questions. That is why I need you to have this number and call me first if you see results that concern you.)

How do donor coordinators support Spanish-speaking donors when the recipient does not survive?

The call informing a donor that the recipient did not survive is one of the most delicate conversations in transplant nursing, and it is complicated by registry anonymity protocols that prevent coordinators from sharing diagnostic details, cause of death, or recipient identity for the first two years after donation. A Spanish-speaking donor who receives a letter notifying them the recipient passed away may call the coordinator line with a question that is essentially: did I cause this? The answer requires two elements. First, what transplant-related mortality means and does not mean: allogeneic stem cell transplantation for hematologic malignancy carries a transplant-related mortality rate that ranges from five percent to thirty percent depending on patient age, comorbidities, disease status at transplant, conditioning regimen intensity, and degree of HLA match. Transplant-related deaths occur from graft failure, opportunistic infection during the nadir period (the two to four weeks when the old immune system is gone and the new one has not yet reconstituted), severe acute GVHD, and multi-organ dysfunction in the early post-transplant period. They are not caused by the donor's cells being unhealthy, incompatible, or insufficient. A donor whose cells successfully engrafted — documented by rising neutrophil counts and chimerism studies showing donor cells producing the recipient's blood — has completed the donation successfully. What happens after engraftment is determined by the recipient's underlying disease, pre-transplant organ reserve, and the biological dynamics of the new immune system in the recipient's body — not by any property of the donation itself. Second, the framing the coordinator can offer without violating registry protocols: the coordinator can confirm that the donation was completed, that the donor followed all instructions, that the donor's health was monitored throughout and found normal, and that any complications the recipient experienced after the donation were not caused by a failure of the donation. The coordinator explaining this in Spanish: '“Puedo decirle que hizo todo bien. Sus células llegaron al receptor. La donación fue exitosa desde el punto de vista médico. Los trasplantes de células madre son tratamientos para enfermedades muy graves, y a veces los pacientes no sobreviven — no por algo que salió mal con la donación, sino por la gravedad de la enfermedad que los llevó a necesitar el trasplante. Su decisión de donar fue un acto de generosidad que le dio al receptor una oportunidad que no hubiera tenido de otra manera. Eso no cambia con lo que pasó después.”' (I can tell you that you did everything right. Your cells reached the recipient. The donation was medically successful. Stem cell transplants are treatments for very serious diseases, and sometimes patients do not survive — not because something went wrong with the donation, but because of the severity of the disease that led them to need the transplant. Your decision to donate was an act of generosity that gave the recipient a chance they would not have had any other way. That does not change with what happened afterward.)

How do donor coordinators explain chronic GVHD to Spanish-speaking related donors who feel responsible?

A related donor who learns the recipient has developed chronic GVHD may call the donor coordinator with a specific set of fears: that her HLA match was not as good as the team said, that there was something genetically wrong with her cells, that the marrow was contaminated during the harvest, or that a decision made during her donation caused this outcome. Each of these fears reflects the donor's lack of a framework for what chronic GVHD is and where it comes from. The explanation requires three components. First, chronic GVHD is not caused by a defective or incompatible donation: chronic GVHD occurs when the donor immune system — which is living inside the recipient's body and producing all of the recipient's blood and immune cells — develops a persistent, dysregulated response against recipient tissues. This is a late immune phenomenon, unrelated to the quality of the marrow, the technique of the harvest, or the strength of the HLA match. HLA matching does not eliminate the possibility of GVHD — it reduces it. Even at 10/10 HLA matching, the immune cells in the donor marrow carry minor histocompatibility antigens that are not captured in HLA typing and that the new immune system may react to over time. This is a property of the biology of allogeneic transplantation, not of the donor's cells. Second, chronic GVHD is in part a marker of a successful engraftment: the donor immune system that is causing chronic GVHD is the same donor immune system that eliminated the recipient's leukemia through the graft-versus-leukemia effect. A recipient with no donor immune system would have no GVHD — and also no graft-versus-leukemia protection. The presence of chronic GVHD indicates that the donor immune system engrafted, is active, and is producing the recipient's blood. Third, chronic GVHD is a medical condition with a specific treatment, not a punishment or a consequence of a mistake: ruxolitinib, ibrutinib, ECP (extracorporeal photopheresis), and low-dose steroids are used to modulate the dysregulated immune response. The goal is to control the immune activation in target tissues without suppressing the anti-leukemia protection. The coordinator explaining this in Spanish: '“La EICH crónica no es una señal de que su médula estuviera mal. Es una señal de que las células que usted donó llegaron, se implantaron, y están produciendo el sistema inmune de su hermano. Lo que ocurre es que ese sistema inmune nuevo — que es el suyo trasplantado — tiene una relación con el cuerpo de su hermano que no es todavía de tolerancia completa en esos tejidos específicos. Eso ocurre en algunos pacientes después de un trasplante exitoso. No lo causó usted. Lo causó la biología del trasplante. Y tiene tratamiento.”' (Chronic GVHD is not a sign that your marrow was bad. It is a sign that the cells you donated arrived, implanted, and are producing your brother's immune system. What is happening is that that new immune system — which is yours, transplanted — has a relationship with your brother's body that is not yet one of complete tolerance in those specific tissues. That happens in some patients after a successful transplant. You did not cause it. The biology of the transplant caused it. And it has treatment.)

What do Spanish-speaking stem cell donors need to know about the apheresis procedure?

Apheresis for peripheral blood stem cell collection is a procedure most donors have no frame of reference for. They know blood donation: a needle in one arm, a bag, ten minutes. Apheresis is different in ways that require advance explanation in the donor's language. The procedure uses two IV lines — one to draw blood out, one to return it. Blood passes through the apheresis machine, which spins it to separate components by density. Stem cells are collected in a fraction that also contains some white blood cells and platelets. The remaining components — red cells, plasma, most platelets — are returned to the donor continuously. The procedure takes four to six hours. The donor feels cold (the returned blood is cooler than body temperature), may experience tingling and muscle cramps around the mouth and hands (caused by citrate, the anticoagulant in the apheresis circuit, which temporarily binds calcium), and may feel lightheaded if blood pressure drops slightly during return. Calcium supplementation — Tums or IV calcium gluconate — is standard during apheresis and prevents or resolves the tingling immediately. The donor's platelet count falls during collection and recovers over seven to ten days. Many donors feel fatigued for two to three days after collection. The coordinator explaining in Spanish before apheresis day: '“El procedimiento dura entre cuatro y seis horas. No van a extraer toda su sangre — la máquina la procesa en circuito continuo: sale por un brazo, pasa por la máquina que separa las células madre, y regresa por el otro. En ningún momento está usted sin la mayoría de su sangre. El frío que va a sentir viene de la sangre que regresa a temperatura de la máquina — es normal. Los hormigueos alrededor de la boca y en las manos son del anticoagulante que usamos en el circuito — le vamos a dar calcio de inmediato si los siente, y los hormigueos se van en minutos. Al terminar va a tener las plaquetas más bajas de lo normal, y eso se recupera solo en una semana. No significa que perdió plaquetas permanentemente — la médula ya está produciendo más.”' (The procedure lasts between four and six hours. They are not going to extract all your blood — the machine processes it in a continuous circuit: it goes out from one arm, passes through the machine that separates the stem cells, and returns through the other. At no point are you without most of your blood. The cold you are going to feel comes from the blood returning at machine temperature — that is normal. The tingling around the mouth and in the hands comes from the anticoagulant we use in the circuit — we will give you calcium immediately if you feel them, and the tingling goes away in minutes. When you finish, your platelets will be lower than normal, and that recovers on its own in a week. It does not mean you permanently lost platelets — the marrow is already producing more.)

What are the most important Spanish phrases for stem cell donor coordinators?

Stem cell donor coordination involves four foundational communication gaps with Spanish-speaking donors that directly shape whether the donation occurs, how the donor experiences the procedure, how the donor processes a recipient's death, and whether a donor who learns about the recipient's chronic GVHD understands that she is not responsible for a complication she did not cause. The first is G-CSF mobilization: '“El G-CSF hace exactamente lo que necesitamos que haga: empuja las células madre de la médula a la sangre. Los glóbulos blancos van a subir mucho — a veces a 70,000 o más — y las plaquetas van a bajar un poco. Eso parece alarmante en un análisis, pero es la prueba de que el medicamento funcionó. El dolor de huesos del cuarto día es porque la médula está tan llena de células que presiona la cubierta del hueso. Ibuprofeno ayuda. Pasa en 24 horas después de la última inyección.”' (G-CSF does exactly what we need it to do: it pushes stem cells from the marrow into the blood. White blood cells are going to rise a lot — sometimes to 70,000 or more — and platelets will fall a bit. That looks alarming on a test, but it is proof that the medication worked. The bone pain on day four is because the marrow is so full of cells that it presses on the covering of the bone. Ibuprofen helps. It passes within 24 hours of the last injection.) The second is recipient death notification: '“Hizo todo bien. Sus células llegaron. La donación fue exitosa. Los trasplantes son para enfermedades muy graves, y algunos pacientes no sobreviven a las complicaciones del proceso — no a la donación, sino a la enfermedad y a la intensidad del tratamiento. Lo que usted hizo le dio al receptor una oportunidad que no hubiera tenido de otra manera. Eso es permanente.”' (You did everything right. Your cells arrived. The donation was successful. Transplants are for very serious diseases, and some patients do not survive the complications of the process — not from the donation, but from the disease and the intensity of the treatment. What you did gave the recipient a chance they would not have had any other way. That is permanent.) The third is chronic GVHD and donor guilt: '“La EICH crónica no vino de su médula siendo defectuosa o incompatible. Vino del sistema inmune que usted donó — que está vivo y funcionando en el cuerpo del receptor — ajustándose a un ambiente que todavía no reconoce completamente como propio. Lo que tiene su hermano ahora es el efecto tardío de un trasplante que funcionó. No es un fallo del trasplante. No es algo que usted causó.”' (Chronic GVHD did not come from your marrow being defective or incompatible. It came from the immune system you donated — which is alive and functioning in the recipient's body — adjusting to an environment it does not yet fully recognize as its own. What your brother has now is the late effect of a transplant that worked. It is not a transplant failure. It is not something you caused.) The fourth is apheresis preparation: '“La máquina procesa su sangre en circuito continuo. Sale, separa las células madre, regresa. Cuatro a seis horas. Va a sentir frío y posiblemente hormigueos — ambos los controlamos de inmediato. Al terminar va a estar cansado y las plaquetas van a estar bajas. Todo se recupera en una semana.”' (The machine processes your blood in a continuous circuit. It goes out, separates the stem cells, returns. Four to six hours. You will feel cold and possibly tingling — both we control immediately. When you finish you will be tired and your platelets will be low. Everything recovers in a week.)

July 29, 2026 · Clinical Spanish · Stem Cell Donation · Bone Marrow Transplant · Donor Coordination

Spanish for hematopoietic stem cell donors — the donor whose blood counts changed after G-CSF mobilization and who nearly canceled, the unrelated donor notified that the recipient did not survive, and the related donor who learned the recipient has chronic GVHD and believes her marrow caused it

Valentina Cruz is 34. She is a school librarian from Phoenix who has worked in the same elementary school for nine years. She knows every child in her library by reading level and by the book that made them stop seeing reading as a chore. She is steady and precise and not prone to panic.

Her brother Miguel, 38, was diagnosed with acute myeloid leukemia seven months ago. He underwent induction chemotherapy, achieved complete remission at day 30, and was referred for allogeneic stem cell transplantation when his cytogenetic risk profile indicated that remission alone would not be durable. The medical team searched for an HLA-matched donor. Valentina was a 10/10 match.

She agreed without hesitation. She completed the donor health evaluation. She read the information packet. She began the five-day course of subcutaneous G-CSF injections that would mobilize her stem cells from the marrow into the bloodstream for collection by apheresis.

On the morning of day four, she woke at 5 a.m. with bone pain so severe she needed to grip the side of the bed to stand. Her sternum ached when she breathed deeply. Both hips felt bruised from the inside. Her temperature was 99.4°F. She drove to the collection center for her pre-apheresis complete blood count.

The result came back: white blood cell count 68,400. Neutrophils 62,000. Platelets 98,000.

Valentina stared at the printout. She had never seen counts like this. She did not know what they meant. What she knew was that these numbers did not look like anything that should be happening inside a healthy person. She pulled out her phone and typed WBC 68000 into the search bar before she stopped herself and called the donor coordinator’s number instead.

That call is one of the most important calls in peripheral blood stem cell donation nursing.

What this post covers

This post covers three conversations that recur in stem cell donor coordination when the donor speaks Spanish. The first is Valentina’s — the sibling donor four days into G-CSF mobilization who sees pre-apheresis blood counts that terrify her and nearly convince her to cancel a donation her brother’s life depends on, because no one has explained in language she can use what G-CSF does to the blood and why the alarming-looking results are proof that the mobilization is working exactly as intended. The second is Alejandro Ríos, 41, a machinist from Denver who registered with the national marrow registry six years ago, donated peripheral blood stem cells to an anonymous recipient eight months ago, and has just received a letter informing him that the recipient passed away — he calls the donor coordinator line wanting to know what happened and whether something he did caused the recipient’s death. The third is Isabel Fuentes, 29, a graduate student from Miami who donated bone marrow via conventional hip harvest to her brother Carlos, 32, eighteen months ago, and calls the donor coordinator nurse after learning that Carlos has developed chronic graft-versus-host disease affecting his skin and eyes — she is calling to ask whether her marrow was defective, whether the HLA match was not as good as the team said, or whether there was something done during the harvest that caused this complication.

In each case the communication failure has the same underlying structure: the donor received a biological event they could not interpret because no one had given them the framework to interpret it, and the absence of that framework converted a normal or expected outcome into an apparent catastrophe. Valentina received blood count values without a mental model of what G-CSF does to the marrow and why those values are diagnostic of a successful mobilization rather than a medical emergency. Alejandro received a notification of recipient death without a framework for what transplant-related mortality means and whether the donation could have contributed to it. Isabel received the diagnosis of a complication in her brother without understanding that chronic GVHD is a property of the biology of allogeneic transplantation, not a defect of the donor’s cells, the precision of the HLA match, or anything that occurred during the donation itself.

Scenario one: Valentina and the blood counts that look like a crisis

Donor coordinator nurse Carmen Soto picks up on the second ring. She has been a donor coordinator for eight years, and she has taken this call — some version of this call — more times than she can count. She knows the moment she hears the tone of the caller’s voice whether it is panic, confusion, or something in between.

Valentina’s voice is controlled but tight.

Valentina: — Me dieron los resultados de los análisis de esta mañana y los números son muy raros. Los glóbulos blancos están en 68,400. Las plaquetas están en 98,000. No sé si debo venir todavía a la aferesis o si hay algo mal. También tengo mucho dolor en los huesos y fiebre.

They gave me the results of this morning’s blood work and the numbers are very strange. The white blood cells are at 68,400. The platelets are at 98,000. I do not know whether I should still come to the apheresis or whether something is wrong. I also have a lot of bone pain and a low fever.

Carmen: — Valentina, gracias por llamarme. Lo primero que necesito que sepa: esos resultados son exactamente lo que queríamos ver esta mañana. No hay nada malo. De hecho, esos números me dicen que el G-CSF funcionó perfectamente. ¿Puedo explicarle lo que está pasando en su cuerpo ahora mismo?

Valentina, thank you for calling me. The first thing I need you to know: those results are exactly what we wanted to see this morning. There is nothing wrong. In fact, those numbers tell me that the G-CSF worked perfectly. Can I explain to you what is happening in your body right now?

Valentina: — Sí. Por favor.

Yes. Please.

What G-CSF does to the bone marrow — and why the blood count looks terrifying

Carmen: — Las células madre de la sangre — las células que el receptor va a necesitar para reconstruir toda su sangre y todo su sistema inmune — viven normalmente dentro de la médula ósea. No circulan en la sangre en números significativos. Están ancladas en la médula en espacios específicos. Para poder recolectarlas por aferesis — sin operar, sin agujas en los huesos — necesitamos empujarlas afuera de la médula hacia la sangre, donde la máquina de aferesis pueda separarlas. Eso es exactamente lo que hace el G-CSF. Es una versión sintética de una proteína que su cuerpo produce naturalmente cuando la médula necesita producir células muy rápido — como después de una infección grave, o después de quimioterapia. Cuando lo damos en las dosis que usted recibió durante cinco días seguidos, pasa esto: la médula empieza a producir células a una velocidad enorme. Las células madre se multiplican rápido y los anclajes moleculares que las sujetan a los nichos de la médula se aflojan. Las células madre salen de la médula a la sangre en cantidades que normalmente no vería. Al mismo tiempo, los neutrófilos — los glóbulos blancos maduros que la médula también está produciendo más rápido — también salen a la sangre. Por eso el conteo de glóbulos blancos llega a 68,000. No es leucemia. No es infección. Es la médula haciendo exactamente lo que le pedimos que hiciera.

The blood stem cells — the cells the recipient will need to rebuild all their blood and all their immune system — normally live inside the bone marrow. They do not circulate in the blood in significant numbers. They are anchored in the marrow in specific spaces. In order to collect them by apheresis — without surgery, without needles in the bones — we need to push them out of the marrow into the blood, where the apheresis machine can separate them. That is exactly what G-CSF does. It is a synthetic version of a protein your body produces naturally when the marrow needs to produce cells very quickly — like after a severe infection, or after chemotherapy. When we give it at the doses you received over five consecutive days, this happens: the marrow starts producing cells at an enormous rate. Stem cells multiply rapidly and the molecular anchors that hold them to the marrow niches loosen. Stem cells leave the marrow into the blood in quantities you would not normally see. At the same time, neutrophils — the mature white blood cells the marrow is also producing faster — also pour into the blood. That is why the white blood cell count reaches 68,000. It is not leukemia. It is not infection. It is the marrow doing exactly what we asked it to do.

Valentina is quiet for a moment.

Valentina: — Entonces el número alto de glóbulos blancos es bueno.

So the high white blood cell count is good.

Carmen: — Es la prueba de que el medicamento funcionó. Un conteo de glóbulos blancos de 68,000 después de cuatro días de G-CSF me dice que la médula respondió bien. Lo que necesitamos para la aferesis son las células madre que están mezcladas en esa sangre. La máquina las va a separar. Entre más células madre haya circulando, más eficiente va a ser la colección. Un conteo alto de glóbulos blancos en este contexto no es una señal de alarma. Es una señal de que tenemos material para trabajar.

It is the proof that the medication worked. A white blood cell count of 68,000 after four days of G-CSF tells me that the marrow responded well. What we need for the apheresis are the stem cells mixed in that blood. The machine is going to separate them. The more stem cells there are circulating, the more efficient the collection is going to be. A high white blood cell count in this context is not an alarm signal. It is a signal that we have material to work with.

Why the bone pain is not an emergency

Valentina: — ¿Y el dolor de huesos? Está muy fuerte. Sobre todo en el estérn y en la pelvis.

And the bone pain? It is very strong. Especially in the sternum and pelvis.

Carmen: — Eso también es lo que esperamos. Le voy a explicar por qué. Los huesos que le duelen más — el estérn, las costillas, la pelvis, los huesos largos — son los que tienen más médula activa. El G-CSF está haciendo que la médula dentro de esos huesos produzca células a una velocidad mucho mayor de lo normal. La médula se llena. Los huesos tienen una cubierta exterior llamada periostio que es sensible a la presión. Cuando la médula se expande rápido, la presión sube contra esa cubierta. Eso produce un dolor profundo y continuo — exactamente lo que usted describe. No es una lesion. No es daño. Es la médula tan activa que los huesos lo sienten. La mayoría de los donantes lo siente más el cuarto y quinto día, que es donde está usted ahora. El ibuprofeno ayuda mucho. Y el dolor se va en 24 horas después de la última inyección, que ya fue ayer.

That is also what we expect. Let me explain why. The bones that hurt the most — the sternum, the ribs, the pelvis, the long bones — are the ones that have the most active marrow. The G-CSF is making the marrow inside those bones produce cells at a rate much higher than normal. The marrow fills up. The bones have an outer covering called the periosteum that is sensitive to pressure. When the marrow expands rapidly, the pressure rises against that covering. That produces a deep and continuous pain — exactly what you are describing. It is not an injury. It is not damage. It is the marrow so active that the bones feel it. Most donors feel it most on day four and five, which is where you are right now. Ibuprofen helps a lot. And the pain goes away within 24 hours after the last injection, which was yesterday.

Valentina: — ¿Y la fiebre?

And the fever?

Carmen: — 99.4 es lo que llamamos subfebrilia — por debajo de 38 grados en escala Celsius, por debajo de 100.4 en Fahrenheit. En cualquier otra persona, eso solo se monitorea. En usted ahora mismo, con los glóbulos blancos en 68,000, no significa infección. Es la respuesta inflamatoria del propio cuerpo a la activación masiva de la médula. Si la fiebre sube por encima de 100.4 o tiene escalosfríos intensos, me llama antes de hacer cualquier otra cosa. Pero lo que tiene ahora no cambia el plan de hoy. ¿Puede venir a la unidad de aferesis en dos horas?

99.4 is what we call low-grade fever — below 38 degrees Celsius, below 100.4 Fahrenheit. In any other person, that is just monitored. In you right now, with white blood cells at 68,000, it does not mean infection. It is the body’s own inflammatory response to the massive marrow activation. If the fever rises above 100.4 or you have intense chills, you call me before doing anything else. But what you have now does not change today’s plan. Can you come to the apheresis unit in two hours?

Valentina: — Sí. Puedo ir. Solo quería entender los números antes de manejar.

Yes. I can go. I just wanted to understand the numbers before driving.

Carmen: — Eso fue exactamente lo correcto. Siempre llame primero. Estos números fuera de contexto asustan — en contexto son lo que necesitamos ver. Nos vemos en dos horas.

That was exactly the right thing to do. Always call first. These numbers out of context are frightening — in context they are what we need to see. We will see you in two hours.

The apheresis procedure: what Valentina needs to know before she arrives

Carmen uses the remaining time in the call to prepare Valentina for the procedure itself, because the apheresis suite is another environment with no prior frame of reference for most first-time donors.

Carmen: — Cuando llegue, le vamos a poner dos accesos venosos — una vía en cada brazo. La máquina va a sacar sangre por un brazo, separar las células madre, y devolver el resto de la sangre por el otro. Todo el tiempo. No es como donar sangre donde le sacan una bolsa y listo. Es un circuito continuo que dura entre cuatro y seis horas.

When you arrive, we are going to place two IV lines — one in each arm. The machine is going to draw blood out through one arm, separate the stem cells, and return the rest of the blood through the other. The whole time. It is not like donating blood where they take a bag and you are done. It is a continuous circuit that lasts four to six hours.

Valentina: — ¿Cuatro a seis horas?

Four to six hours?

Carmen: — Sí. Tráigase algo para leer o ver. Puede estar cómoda — es un sillón reclinable, no es una cama de hospital. Dos cosas que van a pasar: primero, va a sentir frío. La sangre que regresa al cuerpo está a temperatura de la máquina, que es más fría que la temperatura normal del cuerpo. Le vamos a dar mantas. Segundo — y esto es importante — puede sentir hormigueos alrededor de la boca o en las manos. El anticoagulante que usamos en el circuito, que se llama citrato, enlaza calcio temporalmente. Cuando el calcio baja un poco, el sistema nervioso se vuelve más sensible y produce esos hormigueos. No es peligroso. Le vamos a dar calcio de inmediato si lo siente — tabletas masticables de calcio, o calcio intravenoso si los hormigueos son intensos — y los hormigueos se van en minutos. No deje de decirme si los siente. No espere a que empeoren.

Yes. Bring something to read or watch. You can be comfortable — it is a reclining chair, not a hospital bed. Two things are going to happen: first, you are going to feel cold. The blood returning to the body is at machine temperature, which is lower than the body’s normal temperature. We are going to give you blankets. Second — and this is important — you may feel tingling around the mouth or in the hands. The anticoagulant we use in the circuit, called citrate, temporarily binds calcium. When calcium drops a bit, the nervous system becomes more sensitive and produces that tingling. It is not dangerous. We are going to give you calcium immediately if you feel it — chewable calcium tablets, or IV calcium if the tingling is intense — and the tingling goes away in minutes. Do not wait to tell me if you feel it. Do not wait for it to get worse.

Valentina: — De acuerdo. Una pregunta más — después de la aferesis, ¿mis conteos vuelven a la normalidad solos?

Understood. One more question — after the apheresis, do my counts go back to normal on their own?

Carmen: — Los glóbulos blancos bajan rápido — en 24 a 48 horas van a estar cerca de lo normal, porque ya no hay G-CSF empujándolos afuera. Las plaquetas van a estar más bajas de lo que son ahora después de la aferesis — la máquina recoge algunas junto con las células madre. Se recuperan solas en siete a diez días. La médula ya está produciendo plaquetas nuevas — solo necesitan tiempo para llegar a la sangre. No significa que usted perdió plaquetas permanentemente. Significa que la médula va a ponerse al día en una semana.

White blood cells fall quickly — within 24 to 48 hours they are going to be close to normal, because there is no longer G-CSF pushing them out. Platelets are going to be lower than they are now after the apheresis — the machine collects some along with the stem cells. They recover on their own in seven to ten days. The marrow is already producing new platelets — they just need time to reach the blood. It does not mean you permanently lost platelets. It means the marrow is going to catch up in a week.

There is a pause.

Valentina: — Está bien. Voy. Gracias por explicarme. Nadie me había dicho qué iban a significar los números cuando los viera. Solo me dijeron que fueran a hacer los análisis.

All right. I am going. Thank you for explaining. No one had told me what the numbers would mean when I saw them. They only told me to go get the blood work done.

Carmen: — Eso es lo que voy a cambiar en las instrucciones para el próximo donante. Tiene razón. Los números hay que explicarlos antes de que salgan.

That is what I am going to change in the instructions for the next donor. You are right. The numbers have to be explained before they come out.

Scenario two: Alejandro and the call after the letter

Alejandro Ríos is 41. He is a machinist at a manufacturing plant in Denver. He registered with the national marrow registry six years ago at a health fair at his union hall — a cheek swab, a form, a sticker that said “Be the match.” He thought about it occasionally over the years and then mostly forgot about it.

Eight months ago, he received a call that he was a potential match for a patient who needed a transplant. He completed the confirmatory testing. He was confirmed as the best available match. He took two days off work, went to the apheresis center, and donated peripheral blood stem cells. The coordinator told him the recipient was an adult patient with a blood cancer. He was not told more than that — registry protocol.

He went back to work. He thought about the person sometimes, wondering how they were doing.

Three days ago, a letter arrived from the registry. It informed him that the recipient had passed away. It expressed gratitude for his donation. It listed resources for donor support. It did not explain what happened.

He waited three days before calling. When donor coordinator nurse Elena Morales answers, his voice is measured in the way that only barely covers something underneath.

Alejandro: — Recibió una carta. Dice que la persona que recibió mis células murió. Quiero entender qué pasó. Y quiero saber si algo que yo hice, o algo que estuvo mal con mi donación, contribuyó a lo que le ocurrió.

I received a letter. It says that the person who received my cells passed away. I want to understand what happened. And I want to know whether something I did, or something that was wrong with my donation, contributed to what happened to them.

What transplant-related mortality means — and why it is not caused by the donation

Elena: — Alejandro, gracias por llamar. Me alegra que haya llamado. Voy a ser completamente honesta con usted sobre lo que puedo decirle y lo que no puedo.

Alejandro, thank you for calling. I am glad you called. I am going to be completely honest with you about what I can and cannot tell you.

Elena: — El protocolo del registro no me permite compartir información sobre el diagnóstico del receptor, la causa de muerte, ni ninguna información que pueda identificarle. Eso va a seguir siendo así durante dos años desde la fecha de la donación, que es la política estándar del registro. Lo que sí puedo decirle es esto: la donación fue exitosa desde el punto de vista médico. Sus células llegaron al receptor. Nosotros verificamos el injerto — que las células del donante se implantaron y comenzaron a producir sangre nueva en el receptor. El injerto ocurrió. Eso está en el registro de la donación. El injerto no hubiera ocurrido si las células estuvieran mal o fueran incompatibles.

The registry protocol does not allow me to share information about the recipient’s diagnosis, cause of death, or any information that could identify them. That is going to continue for two years from the date of the donation, which is the registry’s standard policy. What I can tell you is this: the donation was medically successful. Your cells reached the recipient. We verify engraftment — that the donor cells implanted and began producing new blood in the recipient. Engraftment occurred. That is in the donation record. Engraftment would not have occurred if the cells were bad or incompatible.

Alejandro: — Entonces mis células llegaron. Y después ¿qué pasó?

So my cells arrived. And then what happened?

Elena: — No puedo decirle los detalles de lo que ocurrió después. Pero sí puedo explicarle por qué los trasplantes de células madre no siempre salvan la vida del paciente, aunque la donación sea perfecta. ¿Le ayudaría entender eso?

I cannot tell you the specifics of what happened afterward. But I can explain to you why stem cell transplants do not always save the patient’s life, even when the donation is perfect. Would it help to understand that?

Alejandro: — Sí. Necesito entenderlo.

Yes. I need to understand it.

What the transplant treats — and why the disease remains the primary risk

Elena: — Los trasplantes de células madre se usan para enfermedades muy graves — leucemias, linfomas, síndromes mielodisplásicos, otras enfermedades que destruyen la médula ósea. Cuando un médico recomienda un trasplante, está diciendo que sin el trasplante, la probabilidad de que el paciente sobreviva es muy baja. El trasplante es la opción más intensa, más riesgosa, y también la que tiene las mejores probabilidades de curación. Pero “la mejor probabilidad” no es certeza.

Stem cell transplants are used for very serious diseases — leukemias, lymphomas, myelodysplastic syndromes, other diseases that destroy the bone marrow. When a physician recommends a transplant, they are saying that without the transplant, the probability that the patient survives is very low. The transplant is the most intense, most risky, and also the one with the best odds of a cure. But “the best odds” is not certainty.

Elena: — El proceso del trasplante tiene varios momentos donde las cosas pueden ir mal — no por la donación, sino por lo que el cuerpo del receptor ya estaba enfrentando. Primero: el acondicionamiento. Antes del trasplante, el receptor recibe quimioterapia muy intensa para destruir su médula enferma y suprimir su sistema inmune. Ese proceso debilita todo el cuerpo. Segundo: el período de nadir. Después del acondicionamiento y antes de que las células del donante se implanten y empiecen a producir células nuevas, hay un período de dos a cuatro semanas donde el receptor no tiene defensas. Sin glóbulos blancos funcionales, una infección que cualquier persona sana controlaría sin notarlo puede convertirse en sepsis en horas. Tercero: la enfermedad de injerto contra huésped. El sistema inmune del donante — que ahora vive en el cuerpo del receptor — puede reaccionar contra los tejidos del receptor. Cuarto: las complicaciones a largo plazo. Incluso después de un injerto exitoso, la recuperación del sistema inmune tarda uno a dos años. En ese período el receptor es vulnerable. Todo eso — el acondicionamiento, el nadir, la EICH, la vulnerabilidad inmune prolongada — está presente en todos los trasplantes, independientemente de qué tan perfecta fue la donación. Cuando un paciente no sobrevive el trasplante, es por alguna de esas complicaciones — no porque las células del donante fallaron.

The transplant process has several moments where things can go wrong — not because of the donation, but because of what the recipient’s body was already facing. First: conditioning. Before the transplant, the recipient receives very intense chemotherapy to destroy their diseased marrow and suppress their immune system. That process weakens the entire body. Second: the nadir period. After conditioning and before the donor cells implant and start producing new cells, there is a two to four week period where the recipient has no defenses. Without functional white blood cells, an infection that any healthy person would control without noticing can become sepsis in hours. Third: graft-versus-host disease. The donor immune system — which now lives in the recipient’s body — can react against the recipient’s tissues. Fourth: long-term complications. Even after successful engraftment, immune system recovery takes one to two years. During that period the recipient is vulnerable. All of that — conditioning, nadir, GVHD, prolonged immune vulnerability — is present in every transplant, regardless of how perfect the donation was. When a patient does not survive the transplant, it is because of one of those complications — not because the donor’s cells failed.

Alejandro: — ¿Y si hay algo que estuviera mal con mis células, lo sabrían?

And if there was something wrong with my cells, would they know?

Elena: — Sí. Los laboratorios de trasplante hacen estudios de quimerismo — análisis que identifican en la sangre del receptor qué porcentaje de células son de origen del donante y cuál del receptor. Si el injerto ocurrió — que ya le dije que ocurrió — las células del donante llegaron, se implantaron, y estaban produciendo sangre. Eso es lo que el quimerismo confirma. No podemos tener injerto con células defectuosas. Un injerto fallido se ve diferente — los conteos no suben, el quimerismo no muestra células del donante. Eso no fue lo que pasó con su receptor.

Yes. Transplant laboratories do chimerism studies — analyses that identify in the recipient’s blood what percentage of cells are of donor origin and which are from the recipient. If engraftment occurred — which I have already told you it did — the donor cells arrived, implanted, and were producing blood. That is what chimerism confirms. We cannot have engraftment with defective cells. A failed graft looks different — counts do not rise, chimerism does not show donor cells. That is not what happened with your recipient.

A long pause.

Alejandro: — ¿Entonces lo que hice funcionó?

So what I did worked?

Elena: — Su donación funcionó. Sus células le dieron al receptor un trasplante que funcionó. Lo que pasó después — lo que sea que pasó — ocurrió en el contexto de una enfermedad muy grave y de un tratamiento muy intenso. No ocurrió porque algo estuviera mal con usted o con su donación. Usted se registró hace seis años sin saber si alguna vez lo iban a llamar. Le llamaron. Se presentó. Tomó días libres del trabajo. Se sentó cuatro horas en esa silla. Las células llegaron. Eso es lo que usted hizo. No pudo controlar lo que ocurrió después de eso, y no hay nada que le dijera sobre la donación que hubiera cambiado ese resultado.

Your donation worked. Your cells gave the recipient a transplant that worked. What happened afterward — whatever happened — occurred in the context of a very serious disease and a very intense treatment. It did not happen because something was wrong with you or your donation. You registered six years ago without knowing whether they would ever call you. They called. You showed up. You took days off work. You sat in that chair for four hours. The cells arrived. That is what you did. You could not control what happened after that, and there is nothing about the donation that you could have done differently that would have changed that outcome.

Alejandro: — Les di una oportunidad que no tenían de otra manera.

I gave them a chance they did not have any other way.

Elena: — Exactamente eso. Y eso no cambia.

Exactly that. And that does not change.

Scenario three: Isabel and the chronic GVHD her cells did not cause

Isabel Fuentes is 29. She is a graduate student in urban planning at the University of Miami. She was in her second year of the program when her brother Carlos, 32, a high school art teacher from the same neighborhood in Hialeah, was diagnosed with acute lymphoblastic leukemia. Isabel was HLA tested. She was a 10/10 match.

She donated bone marrow through a conventional harvest — a surgical procedure under general anesthesia where marrow is collected from the posterior iliac crests of both hips using special needles. She was in the operating room for two hours. Her hip bones ached for a week. She was back in class in ten days.

The transplant was eighteen months ago. Carlos achieved engraftment, completed his immunosuppression taper, and returned to teaching part-time at month twelve. Isabel checked on him every week.

Last week, Carlos called to tell her that his dermatologist had diagnosed a skin condition and his ophthalmologist had told him his dry eyes were caused by something related to the transplant. His hematologist confirmed: chronic graft-versus-host disease, involving the skin and lacrimal glands. Carlos had said it matter-of-factly, because he had just left the clinic and was tired of medical news and did not want to worry her.

Isabel hung up and called the donor coordinator number.

Donor coordinator nurse Rosa Gutiérrez picks up and hears the question Isabel has been rehearsing since she got off the phone with Carlos.

Isabel: — Mi hermano tiene la enfermedad de injerto contra huésped. Crónica. Quiero entender si esto ocurrió porque algo estaba mal con mi médula, o porque la compatibilidad no era tan perfecta como dijeron, o porque algo pasó durante la cosecha de la médula.

My brother has graft-versus-host disease. Chronic. I want to understand whether this happened because something was wrong with my marrow, or because the compatibility was not as perfect as they said, or because something happened during the marrow harvest.

What chronic GVHD is — and where it comes from

Rosa: — Isabel, me alegra que haya llamado. Voy a explicarle exactamente lo que es la EICH crónica y de dónde viene, porque la respuesta a cada una de sus preguntas es: no. No fue por algo defectuoso en su médula. No fue porque la compatibilidad fuera mala. No fue por algo que pasó durante la cosecha. Pero para que tenga sentido, necesito que primero entienda qué es lo que está pasando en el cuerpo de Carlos ahora mismo. ¿Puedo explicarle?

Isabel, I am glad you called. I am going to explain to you exactly what chronic GVHD is and where it comes from, because the answer to each of your questions is: no. It was not because of something defective in your marrow. It was not because the compatibility was bad. It was not because of something that happened during the harvest. But for that to make sense, I need you to first understand what is happening in Carlos’s body right now. Can I explain?

Isabel: — Sí.

Yes.

Rosa: — Cuando Carlos recibió su médula, recibió más que solo células madre que producen sangre. Recibió un sistema inmune completo — el suyo. Las células T que estaban en su médula — los linfocitos que son los soldados del sistema inmune — son, en este momento, el sistema inmune de Carlos. Toda la sangre que Carlos tiene ahora viene de sus células. Todo el sistema de defensa que Carlos tiene ahora viene de sus células. Ese sistema inmune que usted donó aprendió, durante toda su vida, a reconocer el cuerpo de usted como propio y el cuerpo de cualquier otra persona como externo. Cuando ese sistema inmune llegó al cuerpo de Carlos — un cuerpo genéticamente diferente, aunque sean hermanos y tengan el mismo HLA — empezó a aprender cuál es su nuevo hogar. Para la mayoría de los tejidos de Carlos, ese proceso de aprendizaje ocurre bien. Pero en algunos pacientes, el sistema inmune del donante nunca llega a una tolerancia completa en ciertos tejidos — las glándulas lagrimales, la piel, la mucosa oral. En esos tejidos, el sistema inmune continúa reaccionando de forma leve y sostenida, como si todavía no los reconociera del todo como propios. Eso es la EICH crónica. No es porque su médula estuviera mal. Es porque el proceso de tolerancia del sistema inmune en esos tejidos específicos no llegó al punto final que todos queremos.

When Carlos received your marrow, he received more than just stem cells that produce blood. He received a complete immune system — yours. The T cells that were in your marrow — the lymphocytes that are the soldiers of the immune system — are, at this moment, Carlos’s immune system. All the blood Carlos has now comes from your cells. All the defense system Carlos has now comes from your cells. That immune system you donated learned, throughout your entire life, to recognize your body as self and anyone else’s body as external. When that immune system arrived in Carlos’s body — a genetically different body, even though you are siblings and share the same HLA — it began to learn which is its new home. For most of Carlos’s tissues, that learning process goes well. But in some patients, the donor immune system never reaches complete tolerance in certain tissues — the lacrimal glands, the skin, the oral mucosa. In those tissues, the immune system continues to react mildly and persistently, as though it still does not fully recognize them as its own. That is chronic GVHD. It is not because your marrow was bad. It is because the immune tolerance process in those specific tissues did not reach the endpoint we all want.

Isabel: — Pero somos 10 de 10 en HLA. Me dijeron que era la mejor compatibilidad posible.

But we are 10 out of 10 on HLA. They told me it was the best possible compatibility.

Why 10/10 HLA matching does not eliminate GVHD

Rosa: — Eso es cierto y también es incompleto, y es una de las partes más importantes del trasplante que los donantes raramente reciben explicadas bien. La compatibilidad HLA mide doce moléculas específicas en la superficie de las células que el sistema inmune usa para identificar lo propio. Cuando un donante y un receptor comparten las mismas doce moléculas, eso es 10 de 10, o según el sistema de tipificación, 12 de 12. Es la compatibilidad más alta que podemos medir. Pero hay cientos — posiblemente miles — de otras moléculas en la superficie de las células que no se miden en la tipificación HLA estándar. Se llaman antígenos de histocompatibilidad menor. Entre hermanos, incluso entre gemelos no idénticos con HLA idéntico, esas moléculas pequeñas pueden ser diferentes. El sistema inmune que usted donó puede reconocer esas diferencias menores en los tejidos de Carlos y producir la reacción suave y sostenida que llamamos EICH crónica. Esto ocurre en el 30 a 50 por ciento de los pacientes que reciben un trasplante alogénico de un donante familiar HLA-idéntico. No es una excepción. Es una complicación reconocida del trasplante que los médicos conocen y para la que tienen tratamiento. Y absolutamente no tiene relación con si su médula era defectuosa o si la cosecha no se hizo bien.

That is true and also incomplete, and it is one of the most important parts of the transplant that donors rarely receive well explained. HLA compatibility measures twelve specific molecules on the surface of cells that the immune system uses to identify what is self. When a donor and a recipient share the same twelve molecules, that is 10 out of 10, or depending on the typing system, 12 out of 12. It is the highest compatibility we can measure. But there are hundreds — possibly thousands — of other molecules on the surface of cells that are not measured in standard HLA typing. They are called minor histocompatibility antigens. Between siblings, even between non-identical twins with identical HLA, those small molecules can differ. The immune system you donated may recognize those minor differences in Carlos’s tissues and produce the mild, sustained reaction we call chronic GVHD. This occurs in 30 to 50 percent of patients who receive an allogeneic transplant from an HLA-identical family donor. It is not an exception. It is a recognized complication of transplantation that physicians know about and have treatment for. And it has absolutely no relationship to whether your marrow was defective or whether the harvest was not done correctly.

Isabel: — ¿Y el hecho de que fue cosecha convencional — de la cadera — en lugar de aferesis de sangre periférica? ¿Eso tiene algo que ver?

And the fact that it was a conventional harvest — from the hip — rather than peripheral blood apheresis? Does that have anything to do with it?

Rosa: — Es una pregunta excelente y la respuesta es: no, no fue la causa de la EICH crónica de Carlos. Pero sí existe una relación entre el tipo de fuente del trasplante y la probabilidad de EICH que vale la pena explicar, porque demuestra que esto no fue una decisión mal tomada. La médula cosechada de la cadera tiene menos linfocitos T — menos células T del sistema inmune — que las células madre de sangre periférica recolectadas por aferesis. Eso significa que, en promedio, la cosecha convencional de médula tiene una tasa algo menor de EICH aguda que la colección de sangre periférica. Para Carlos, que tiene una enfermedad de riesgo intermedio, el equipo médico muy probablemente eligió la cosecha de médula precisamente para reducir el riesgo de EICH. No lo eliminaron, porque el trasplante alogénico siempre lleva algún riesgo de EICH. Pero no tomaron la decisión que aumenta ese riesgo. La EICH crónica ocurrió a pesar de la mejor compatibilidad y de la fuente con menor riesgo de EICH que existía para Carlos. Eso es la biología del trasplante. No es un error.

That is an excellent question and the answer is: no, it was not the cause of Carlos’s chronic GVHD. But there is a relationship between the type of transplant source and the probability of GVHD that is worth explaining, because it demonstrates that this was not a poorly made decision. Marrow harvested from the hip has fewer T lymphocytes — fewer T cells of the immune system — than peripheral blood stem cells collected by apheresis. That means that, on average, conventional marrow harvest has a somewhat lower rate of acute GVHD than peripheral blood collection. For Carlos, who has an intermediate-risk disease, the medical team most likely chose the marrow harvest precisely to reduce the risk of GVHD. They did not eliminate it, because allogeneic transplantation always carries some GVHD risk. But they did not make the decision that increases that risk. Chronic GVHD occurred despite the best compatibility and the lower GVHD risk source that existed for Carlos. That is the biology of transplantation. It is not an error.

Isabel: — ¿Y Carlos va a poder manejarlo?

And Carlos is going to be able to manage it?

Rosa: — La EICH crónica tiene tratamiento. El equipo de trasplante va a volver a iniciar inmunosupresión — generalmente prednisona a dosis baja, a veces con ruxolitinib o ibrutinib como segundo agente — más tratamientos de protección para los tejidos directamente afectados. Para los ojos: lágrimas artificiales sin conservantes, a veces sueros oculares con factores de crecimiento; para la piel: emolientes, corticosteroides tópicos, protección solar. La EICH crónica en muchos pacientes se controla bien. En algunos remite completamente. En otros requiere manejo a largo plazo. Pero no es la leucemia regresando. Carlos sigue en remisión. Lo que tiene ahora es un sistema inmune propio — el que usted le donó — que sigue adaptándose. Y ese proceso tiene un manejo médico establecido.

Chronic GVHD has treatment. The transplant team is going to reinitiate immunosuppression — usually low-dose prednisone, sometimes with ruxolitinib or ibrutinib as a second agent — plus protective treatments for the directly affected tissues. For the eyes: preservative-free artificial tears, sometimes serum eye drops with growth factors; for the skin: emollients, topical corticosteroids, sun protection. Chronic GVHD in many patients is well controlled. In some it remits completely. In others it requires long-term management. But it is not the leukemia returning. Carlos remains in remission. What he has now is an immune system of his own — the one you donated — that continues adapting. And that process has an established medical management.

Isabel is quiet for a long moment.

Isabel: — Entonces Carlos está vivo y en remisión porque yo doné. Y la EICH crónica que tiene ahora es una complicación del trasplante que lo curó, no un error que yo cometió.

So Carlos is alive and in remission because I donated. And the chronic GVHD he has now is a complication of the transplant that cured him, not a mistake I made.

Rosa: — Exactamente eso. Es la biología del sistema inmune que usted le dio. Ese mismo sistema inmune que tiene la EICH crónica es el que produce toda la sangre de Carlos y el que eliminó la leucemia. No son cosas separadas. Es el mismo sistema inmune haciendo cosas distintas en distintos tejidos. Y tiene tratamiento.

Exactly that. It is the biology of the immune system you gave him. That same immune system that has chronic GVHD is the one that produces all of Carlos’s blood and the one that eliminated the leukemia. They are not separate things. It is the same immune system doing different things in different tissues. And it has treatment.

Eight practical phrases for stem cell donor coordinators

These are the phrases that recur in stem cell donor coordination when the donor speaks Spanish. Each one addresses a communication gap that directly shapes whether the donation occurs, how the donor experiences a medically alarming but expected procedure, how the donor processes a recipient’s death without a framework for what that means, and whether a donor who has just learned of a complication in the recipient understands that she did not cause it.

1. The high white blood cell count after G-CSF is proof the medication worked, not a sign of disease

El G-CSF empujó las células madre de la médula a la sangre. Los glóbulos blancos subieron a ese nivel porque la médula está respondiendo exactamente como le pedimos. Un conteo de 60,000 a 80,000 después de cuatro días de G-CSF no significa leucemia, no significa infección, no significa emergencia. Significa que tenemos células madre circulando en la sangre para recolectar hoy.

G-CSF pushed the stem cells from the marrow into the blood. The white blood cells rose to that level because the marrow is responding exactly as we asked. A count of 60,000 to 80,000 after four days of G-CSF does not mean leukemia, does not mean infection, does not mean emergency. It means we have stem cells circulating in the blood to collect today.

2. Bone pain on day four of G-CSF is the expected sign of a full marrow — it is not an injury and it resolves within 24 hours of the last injection

El dolor en el estérn, las costillas, la pelvis, y los huesos largos es porque la médula está tan llena de células que presiona la cubierta del hueso. Es la señal de que el G-CSF hizo su trabajo. Ibuprofeno ayuda. Pasa en 24 horas después de la última inyección. No es un daño. Es el resultado de una médula tan activa que los huesos lo sienten.

The pain in the sternum, ribs, pelvis, and long bones is because the marrow is so full of cells that it presses on the covering of the bone. It is the sign that G-CSF did its job. Ibuprofen helps. It passes within 24 hours of the last injection. It is not an injury. It is the result of marrow so active that the bones feel it.

3. Tingling during apheresis is from citrate binding calcium — report it immediately and it resolves in minutes with calcium supplementation

Si siente hormigueos alrededor de la boca o en las manos durante la aferesis, dígamelo de inmediato. No espere. El anticoagulante en el circuito enlaza calcio temporalmente y eso baja el calcio libre, lo que hace al sistema nervioso más sensible. Le vamos a dar calcio de inmediato — tabletas o intravenoso — y los hormigueos se van en minutos. No es peligroso, pero sí necesito saberlo cuando lo siente, no diez minutos después.

If you feel tingling around the mouth or in the hands during apheresis, tell me immediately. Do not wait. The anticoagulant in the circuit temporarily binds calcium and that lowers free calcium, which makes the nervous system more sensitive. We are going to give you calcium immediately — tablets or intravenous — and the tingling goes away in minutes. It is not dangerous, but I need to know when you feel it, not ten minutes later.

4. Engraftment confirmed means the donation worked — transplant-related mortality is caused by the disease and the intensity of treatment, not the donation itself

Si el injerto ocurrió — si las células del donante se implantaron y empezaron a producir sangre en el receptor — la donación funcionó. Cuando un paciente no sobrevive el trasplante, es por complicaciones del tratamiento — infección durante el período de nadir, EICH severa, falla orgánica — no por algo que estuviera mal con las células del donante. Un injerto exitoso con las células del donante no puede ocurrir si las células estuvieran defectuosas o incompatibles.

If engraftment occurred — if the donor cells implanted and started producing blood in the recipient — the donation worked. When a patient does not survive the transplant, it is because of treatment complications — infection during the nadir period, severe GVHD, organ failure — not because something was wrong with the donor’s cells. A successful engraftment with the donor’s cells cannot occur if the cells were defective or incompatible.

5. The donor gave the recipient a chance that did not exist without them — that is permanent regardless of what happened after

La donación le dio al receptor una posibilidad que no existía sin usted. Los trasplantes son para enfermedades con muy bajas probabilidades de sobrevivir sin tratamiento definitivo. El trasplante es el tratamiento definitivo. Lo que ocurrió después es la enfermedad actuando sobre un cuerpo que ya estaba muy comprometido por el diagnóstico y la intensidad del tratamiento. La generosidad del acto de usted no depende del resultado del receptor. Eso es permanente.

The donation gave the recipient a possibility that did not exist without you. Transplants are for diseases with very low odds of surviving without definitive treatment. The transplant is the definitive treatment. What happened afterward is the disease acting on a body already heavily compromised by the diagnosis and the intensity of treatment. The generosity of your act does not depend on the recipient’s outcome. That is permanent.

6. Chronic GVHD is not caused by defective donor marrow — it is the late biology of the donor immune system adapting to the recipient’s tissues

La EICH crónica no significa que su médula estuviera mal. Significa que el sistema inmune que usted donó — que ahora vive en el cuerpo del receptor y produce toda su sangre — no llegó a tolerancia completa en ciertos tejidos específicos. Eso ocurre en el 30 a 50 por ciento de los trasplantes alogénicos entre familiares HLA-idénticos. No es un error. Es la biología del trasplante, y tiene tratamiento.

Chronic GVHD does not mean your marrow was bad. It means the immune system you donated — which now lives in the recipient’s body and produces all their blood — did not reach complete tolerance in certain specific tissues. That happens in 30 to 50 percent of allogeneic transplants between HLA-identical family donors. It is not an error. It is the biology of transplantation, and it has treatment.

7. 10/10 HLA matching reduces GVHD but does not eliminate it because minor histocompatibility antigens are not captured in standard HLA typing

La compatibilidad 10 de 10 en HLA mide doce moléculas específicas. Es la mejor compatibilidad que podemos medir y reduce mucho el riesgo de EICH comparado con un donante no relacionado. Pero hay cientos de otras moléculas en la superficie de las células que no se miden — los antígenos de histocompatibilidad menor — que pueden ser diferentes incluso entre hermanos con HLA idéntico. El sistema inmune del donante puede reconocer esas diferencias pequeñas y producir una reacción sostenida en tejidos específicos. No es porque la compatibilidad fuera mala. Es porque la compatibilidad perfecta medible no es la misma que la compatibilidad total biológica.

10 out of 10 HLA compatibility measures twelve specific molecules. It is the best compatibility we can measure and greatly reduces the risk of GVHD compared to an unrelated donor. But there are hundreds of other molecules on the surface of cells that are not measured — the minor histocompatibility antigens — that can differ even between siblings with identical HLA. The donor immune system may recognize those small differences and produce a sustained reaction in specific tissues. It is not because the compatibility was bad. It is because measurable perfect compatibility is not the same as total biological compatibility.

8. Chronic GVHD treatment restores immunosuppression to control the donor immune response in affected tissues without eliminating the anti-leukemia protection

El tratamiento de la EICH crónica reinstala inmunosupresión — prednisona a dosis baja, con ruxolitinib si los esteroides solos no son suficientes — más cuidado local de los tejidos afectados. El objetivo es controlar la reacción del sistema inmune en esos tejidos sin apagarlo completamente. El mismo sistema inmune que tiene la EICH también protege contra la leucemia. El tratamiento busca el equilibrio: suprimir lo que daña los tejidos sin perder lo que protege contra la enfermedad.

Chronic GVHD treatment reinstates immunosuppression — low-dose prednisone, with ruxolitinib if steroids alone are not enough — plus local care for the affected tissues. The goal is to control the immune system’s reaction in those tissues without extinguishing it completely. The same immune system that has GVHD also protects against leukemia. Treatment seeks the balance: suppress what damages the tissues without losing what protects against the disease.

Why these three conversations share the same underlying structure

Valentina, Alejandro, and Isabel arrived at their calls in very different situations — Valentina on the morning of the procedure that had a direct bearing on her brother’s survival, holding a blood test result that looked like a medical crisis and had no language to interpret it as anything else; Alejandro three days after opening a letter that told him the person he donated to was dead, with no framework for whether the donation could have contributed to that outcome; Isabel hours after learning her brother has a complication she has never heard of, with no framework for where it comes from or whether it is her fault.

In each case the communication failure has the same structure: the donor was given an outcome without the biological framework that makes that outcome interpretable. Valentina was told to come in for pre-apheresis blood work. She was not told what G-CSF does to the marrow, why the expected lab values look alarming, or what to do when she sees them. Alejandro was told his donation was complete and that he might receive future communications from the registry. He was not told what transplant-related mortality means or why a successful engraftment is incompatible with a defective donation. Isabel was told her HLA was 10/10 and the transplant was successful. She was not told that 10/10 HLA matching does not eliminate minor histocompatibility antigen differences, that chronic GVHD occurs in nearly half of HLA-identical family donor transplants, or that the biology of the complication has nothing to do with the quality of the donated marrow.

The stem cell donor coordinator who provides that framework in Spanish does not change any outcome. She translates the biology into a form the donor can integrate before the outcome demands interpretation. Valentina goes to the apheresis chair understanding that the terrifying WBC of 68,400 is the proof the mobilization worked, not the sign of a crisis she caused by agreeing to donate. Alejandro goes back to his life in Denver with something he can say to himself that is both true and complete: his cells arrived, the donation was successful, and the recipient’s death was not his. Isabel goes back to checking on her brother understanding that the chronic GVHD affecting his skin and eyes is the late expression of the immune system she gave him doing what that immune system does in a body it is still learning, and that the treatment for it is specific and established and not a response to anything she did wrong.

In stem cell donor coordination, clinical Spanish is not vocabulary for medical procedures. It is the language of mechanism, context, and causation. Valentina does not need the word for “apheresis.” She needs to hear why the number on the page in front of her is the evidence of success, not the onset of catastrophe — before she decides whether to drive to the collection center or drive home. Alejandro does not need the word for “chimerism.” He needs to hear that the fact that his cells implanted means the donation worked, and that what happened after is what happens to very ill patients who undergo very intensive treatment, and that it did not happen because of him. Isabel does not need the word for “histocompatibility.” She needs to hear that the best HLA match available still carries the biology it carries, that her brother’s chronic GVHD is the late complication of a transplant that saved his life, and that it is not what happened because her marrow was wrong but what happened because transplantation is what it is.

Those are the phrases that clinical Spanish for stem cell donor coordinators must carry. The procedures, the protocols, the registry rules — those are the scaffold. The mechanism is what the donor needs to be able to hold when the outcome arrives in a form no one fully prepared them for.

Practice these conversations

ClinicaLingo’s scenario library includes roleplay practice for stem cell donor coordination conversations with Spanish-speaking donors, covering G-CSF mobilization education before the pre-apheresis CBC, apheresis procedure preparation, compassionate communication after recipient outcomes, and chronic GVHD explanation for related donors. The AI roleplay tool lets you practice these conversations before they happen — speaking the phrases, hearing the donor respond, adjusting your framing in real time.

The free 50-phrase PDF includes the most common clinical-Spanish phrases for hematology and oncology conversations. And the full blog library covers bone marrow transplant nursing, hematology-oncology inpatient nursing, sickle cell disease clinic nursing, transplant nursing, and over 165 other clinical specialties where Spanish-speaking patients and donors frequently encounter information gaps that nurses are positioned to close.

All clinical scenarios in this post are composite and anonymized. Named donors and patients are fictional constructs for educational illustration. The clinical content — G-CSF mobilization physiology, apheresis procedure specifics, transplant-related mortality epidemiology, minor histocompatibility antigen biology, and chronic GVHD treatment approaches including ruxolitinib and ibrutinib — reflects standard transplant practice at the time of publication and is not a substitute for institutional protocols, donor coordinator training programs, or individual clinical judgment. Registry anonymity protocols vary by organization; coordinators should follow their institution’s specific policies for donor communication after recipient outcomes.